Agilent Technologies (A) has just added two fresh product milestones: the BioTek Cytation 9 cell imaging multimode reader and an FDA cleared PD-L1 IHC 22C3 companion diagnostic, giving investors new context for thinking about the stock.
See our latest analysis for Agilent Technologies.
These product launches and the recent dividend announcement come against a mixed backdrop, with a 7 day share price return of 4.75%, a 90 day share price return of 16.29%, and a 3 year total shareholder return of 14.41%. This hints that momentum has cooled following a stronger 1 year total shareholder return of 13.04%.
If advances in tools for cell imaging and cancer diagnostics are on your radar, it could be worth broadening your watchlist with 36 healthcare AI stocks
With Agilent trading at $115.48, carrying a reported intrinsic discount of around 7% and a more than 40% gap to analyst targets, the key question is whether this signals mispricing or if markets already see growth coming.
Most Popular Narrative: 29.2% Undervalued
Agilent's most followed narrative pegs fair value at $163.19 per share against a last close of $115.48, drawing a wide gap that is linked to future growth and margins.
Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.
Want to see what is really backing that valuation gap? Revenue compounding, margin uplift, and a richer earnings mix all sit at the core of this narrative.
Result: Fair Value of $163.19 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on tariff and supply chain pressures not eroding margins and on lab replacement cycles holding up instead of slowing more than analysts expect.
Find out about the key risks to this Agilent Technologies narrative.
Next Steps
Feeling unsure whether the optimism in this article matches your own view? Take a closer look now and weigh the 4 key rewards
Looking for more investment ideas?
Before moving on, take a moment to widen your opportunity set, because the next idea that fits your goals might not be on your radar yet.
- Target potential upside by scanning companies that look mispriced on quality and fundamentals using the 59 high quality undervalued stocks.
- Strengthen your income stream by focusing on reliable payers and higher yields through the 13 dividend fortresses.
- Reduce sleepless nights by zeroing in on companies with steadier profiles via the 68 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com